Torrent Pharma's stock surged to a 52-week high of ₹2,745.55 in the opening trade on March 6 following a favorable inspection by the US FDA. Currently, the stock is trading at ₹2,691.210, up by 1.10%. The USFDA has closed its inspection of Torrent Pharma's Gujarat manufacturing facility, issuing an establishment inspection report (EIR). The inspection, conducted from December 5 to December 11, 2023, focused on the company's oral-oncology manufacturing facility in Bileshwarpura, Gujarat.
In the quarter ending December 2023, Torrent Pharma reported a significant 56.5% increase in net profit, reaching ₹443 Crore. Over the past year, the company's share price has surged by 80%. Torrent Pharmaceuticals Ltd, a part of the ₹37,000 Crore Torrent Group and headquartered in Ahmedabad, is a leading Indian multinational pharmaceutical company. With a presence in over 40 countries and more than 2000 product registrations globally, Torrent Pharma operates in various therapeutic segments, including cardiovascular, central nervous system, gastro-intestinal, and others.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.